Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$6.83 ▲ +0.04
(+0.52%)
MKT CAP: $46.3M • VOL: 57.7K
52W L $6 52W H $18
ROARABLE / RQD
D • 51/100
PIOTROSKI
3 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$6
MEDIAN
$8
MEAN
$8
HIGH
$9
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TIL TAPE
TIL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $8.26 | $7.85 | 2025-02-14 | $6.22 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $8.61 | $8.06 | 2025-02-06 | $6.42 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $7.79 | $7.51 | 2025-01-29 | $6.56 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $6.97 | — | 2025-01-17 | $6.69 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $6.01 | $6.49 | 2025-01-09 | $6.08 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $8.13 | $7.10 | 2024-12-18 | $5.94 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $6.63 | $6.90 | 2024-12-04 | $6.35 | -4.3% | 48% | C |